In SH‐SY5Y NB cells, treatment with BCI led to a dose‐dependent decrease in ERK activity and cell viability, hinting that pharmacological inhibition of DUSP1 and DUSP6 could potentially reduce NB cell growth [21]. This evidence concerns the gene MAPK1 and neuroblastoma.